ライフサイエンスコーパス: rejection episode

1 notype and freedom from first grade > or =3A rejection episode.

2 t accepted the allograft permanently after a rejection episode.

3 redict functional outcome following an acute rejection episode.

4 ents were symptomatic and 7 did not note the rejection episode.

5 months, four patients have not experienced a rejection episode.

6 ment with pulse steroid therapy to treat the rejection episode.

7 418 serum samples, including 35 paired to a rejection episode.

8 Among 98 subjects, 37% had >/=1 rejection episode.

9 and grafts after successful treatment of the rejection episode.

10 drawn due to return of underlying disease or rejection episodes.

11 nd in the early post-ITx period during first rejection episodes.

12 mild (n=4), moderate (n=2), and severe (n=1) rejection episodes.

13 d continuous vigilance is required to detect rejection episodes.

14 c tacrolimus concentrations may induce acute rejection episodes.

15 of bowel on initial endoscopy, and number of rejection episodes.

16 and were evaluated retrospectively regarding rejection episodes.

17 ay in fact be missed concordant kidney acute rejection episodes.

18 ab and three Thymoglobulin patients suffered rejection episodes.

19 al function was attained in patients without rejection episodes.

20 There were no acute rejection episodes.

21 y initial immunosuppression to prevent early rejection episodes.

22 jection and would resolve after treatment of rejection episodes.

23 recipients at increased risk for early acute rejection episodes.

24 y of renal function with a low risk of acute rejection episodes.

25 ) survival, complications, and biopsy-proven rejection episodes.

26 ymocyte Globulin) was used to treat putative rejection episodes.

27 n episodes, and seven experienced mild acute rejection episodes.

28 s or the incidence of biopsy-confirmed acute-rejection episodes.

29 d after immunosuppressive therapy in 9 of 11 rejection episodes.

30 .2%) patients developed a total of six acute rejection episodes.

31 he absence of rejection would predict future rejection episodes.

32 gnificant increase in the incidence of acute rejection episodes.

33 ts on subsequent graft survival or number of rejection episodes.

34 oup of children with no early clinical acute rejection episodes.

35 ifically home to the graft epithelium during rejection episodes.

36 y predict the subsequent occurrence of acute rejection episodes.

37 p, current pharmacological regimen, and late rejection episodes.

38 erved between patients with or without early rejection episodes.

39 correlated positively with mild and moderate rejection episodes.

40 E patients who experienced greater than four rejection episodes.

41 grafts, but not in recipients with multiple rejection episodes.

42 equent (P=0.034) and earlier (P=0.065) acute rejection episodes.

43 resulted in a significant reduction in acute rejection episodes.

44 time points compared with eyes without graft rejection episodes.

45 biopsy, caused by hepatitis C recurrence or rejection episodes.

46 -DSA showed the highest likelihood to suffer rejection episodes.

47 3 years (mean, 28 months) without subsequent rejection episodes.

48 o differences in incidences of biopsy-proven rejection episodes.

49 or glaucoma surgery (P < 0.0001) and a prior rejection episode (0.0023) were the significant risk fac

50 ed viruria was associated with more putative rejection episodes (0.62 vs. 0.33 per patient, P=0.006)

51 to determine the cumulative probability of a rejection episode 1 and 2 years after surgery.

52 . 0.9 mg/dL; P<0.001) and in all grafts with rejection episodes (1.2 vs. 0.9 mg/dL; P<0.05).

53 on, p < 0.05) and hemodynamically comprising rejection episodes (1.3 +/- 1.9 vs. 0.7 +/- 1.3, overall

54 /- 7%), despite an increased number of early rejection episodes (1.7 +/- 1.6 vs. 0.7 +/- 1.3, overall

55 . 25%, P=0.04), more likely to have a second rejection episode (13% vs. 4%; P=0.03), or to have recei

56 ke (3.30 [1.31-8.28]), and one or more acute rejection episode (13.89 [4.78-40.37]).

57 Twenty-seven recipients experienced a rejection episode, 14 of which had CMV disease, mostly a

58 onders exhibited a higher incidence of acute rejection episodes (26%) than either basiliximab-treated

59 2 months, respectively (P<0.001); more acute rejection episodes 28.2% vs. 13.5% (P=0.012); and increa

60 total of 13 (31%) of 42 recipients developed rejection episodes 3 to 49 days after transplantation.

61 uency in the group of patients with multiple rejection episodes (35.1% and 18.4%) compared to rejecti

62 e significantly more likely to have an acute rejection episode (39% vs. 25%, P=0.04), more likely to

63 te), and all predisposed to subsequent acute rejection episodes (4/4), whereas there were no rejectio

64 r than 30 group were more likely to suffer a rejection episode (43% vs. 29%; P = 0.03).

65 that S patients had fewer post-30 day first rejection episodes (5.4%) when compared with the C group

66 In transplants that had a rejection episode, 50% of PKs (17) and 60% of EKs (15) s

67 Most putative rejection episodes (52.1%) occurred concurrently with vi

68 Twenty-two out of 30 rejection episodes (73.3%) resolved with steroid treatme

69 In transplants that had a rejection episode, 85% of PKs (41) and 76% of EKs (22) s

70 Of the 196, 37 (18.9%) had a previous acute rejection episode; 96 (49%) had concurrent i score = 0.

71 e the incidence and clinical course of graft rejection episodes after Descemet membrane endothelial k

72 Rejection episodes after parental liver transplantation

73 survival and reduced the incidence of acute rejection episodes after renal transplantation compared

74 ation, would predict the occurrence of acute rejection episodes after renal transplantation.

75 ients who may be at increased risk for acute rejection episodes after renal transplantation.

76 Thirteen of 14 rejection episodes (all in the no steroid group) resolve

77 The incidence of rejection episodes, allograft nephropathy, and graft los

78 duction of the incidence and the severity of rejection episodes, although we need to follow-up larger

79 id-resistant or Banff grades II or III acute rejection episodes among 14%, 55% (P=0.08), and 71% (P=0

80 ction in the incidence and severity of acute rejection episodes among patients maintained on tacrolim

81 The mean number of rejection episodes among the three infants during the fi

82 In rejection episode analyses, multiple logistic regression

83 pretransplant regulation, seven had an acute rejection episode and four of these experienced graft lo

84 the level of Fas mRNA is reduced during the rejection episode and subsequently recovers.

85 of keratoplasty may be used to anticipate a rejection episode and/or to prevent an allograft rejecti

86 nd 4 mg/day resulted in lower rates of acute rejection episodes and efficacy failure than the 1 mg/da

87 Number of rejection episodes and hospital readmissions during the

88 be beneficial in reducing the occurrence of rejection episodes and improving graft survivals.

89 Patients with graft rejection episodes and late endothelial failure were ide

90 There were no acute rejection episodes and no opportunistic infections.

91 or third-party MSCs resulted in reversal of rejection episodes and prolongation of islet function in

92 variations in susceptibility to early graft rejection episodes and recurrence of hepatitis C infecti

93 Cumulative incidence of rejection episodes and rejection irreversibility rate.

94 in outcome measures: Cumulative incidence of rejection episodes and rejection irreversibility rate.

95 ents had a greater frequency and severity of rejection episodes and required more immunosuppression.

96 us therapy benefited the resolution of acute rejection episodes and significantly reduced the risk of

97 cipients, i.e., patients with no prior acute rejection episodes and stable renal function ("stable" p

98 and the incidence and severity of the acute rejection episodes and to determine the safety and toler

99 id not develop rejection, 123 who showed one rejection episode, and 57 patients who suffered from mul

100 einuria, the occurrence of a post-PAK kidney rejection episode, and interval between kidney and pancr

101 to P interval of over 1 year, pre-PAK kidney rejection episode, and pre-PAK proteinuria.

102 dence of acute tubular necrosis (ATN), acute rejection episodes, and causes of graft failure in perit

103 ysis for more than 1 year, one or more acute rejection episodes, and donor age older than 55.

104 er-risk scores associated with readmissions, rejection episodes, and infections.

105 recipients is a major risk factor for graft rejection episodes, and it has significant financial imp

106 rophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression re

107 rum creatinine level, number and severity of rejection episodes, and patient and graft survival rates

108 neal vascularization, surgical complication, rejection episodes, and postoperative medication were co

109 cluding donor and recipient characteristics, rejection episodes, and serology were prospectively reco

110 severe rejection, three experienced moderate rejection episodes, and seven experienced mild acute rej

111 that occurrence, timing, and number of acute rejection episodes are associated with increased risk of

112 assist device support, overall survival and rejection episodes are comparable to outcomes from conte

113 of anti-HLA antibodies at the time that the rejection episodes are diagnosed.

114 Most acute-rejection episodes are mild and do not lead to clinicall

115 n the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control g

116 ties, on the incidence and severity of acute rejection episodes as well as its tolerability were eval

117 We observed 10 women with rejection episodes associated to pregnancy; these were 8

118 The Kaplan-Meier cumulative probability of a rejection episode at 1 and 2 years was 1% and 1%, respec

119 Kaplan-Meier cumulative probability of a rejection episode at 3, 6, 12, and 24 months was 0%, 0.4

120 tion in the incidence of biopsy-proven acute rejection episodes at 12 months posttransplant (43% vs.

121 therapy and who had not experienced an acute rejection episode before month 6, serum creatinine level

122 surgery (HR, 5.23 [95% CI, 1.47-7.33]), and rejection episodes before PK failure (HR, 3.28 [95% CI,

123 s was used to determine the relative risk of rejection episodes between the 3 groups.

124 One year after the rejection episodes, BSCVA and CCT in these eyes remained

125 with less early CNI nephrotoxicity and fewer rejection episodes, but comparable chronic arteriolar to

126 sive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials

127 yzed for time to first repeat and late acute rejection episodes by race, age at transplantation, and

128 ndependent predictors of CAV were: number of rejection episodes (cause-specific hazard ratio [95% con

129 During acute rejection episodes, CD8(+) T cells can contribute to lun

130 the rejector group, 19 patients presented 26 rejection episodes: clinically suspected (n=19) and biop

131 , fewer endocrine disorders, and fewer acute rejection episodes comparing adjunctive MMF and Tacro vs

132 d the asymptomatic nature of most histologic rejection episodes, controversy exists regarding the nee

133 Patients who underwent rejection episodes could be started on CNI.

134 ndependent predictors of CAV were: number of rejection episodes (CSHR (95% CI): 1.18 [1.04-1.34], p=0

135 vs. cadaveric), native liver disease, acute rejection episodes, cytomegalovirus (CMV) infection, and

136 Statins may prevent fatal rejection episodes, decrease terminal cancer risk, and r

137 biopsy-proven (Banff 1993 criteria) ongoing rejection episodes despite prior treatment with pulse an

138 A graft rejection episode developed in 12 patients (estimated pr

139 It was interesting that there were seven rejection episodes documented by biopsy at the approxima

140 In less severe rejection episodes, DR3 and SODD were more focally induc

141 oid, even a weak one, was protective against rejection episodes during the second year after DMEK, wh

142 A meta-analysis of rejection episodes found no significant benefit on eithe

143 lem, eight terminated because of one or more rejection episodes, four terminated because of adverse e

144 fter transplantation and monitored for acute rejection episodes, graft function, and graft survival.

145 ncidence and severity of biopsy-proven acute rejection episodes, graft survival, patient survival, in

146 Eyes with a graft rejection episode had a higher median percentage decline

147 h recipients with a history of > or =1 acute rejection episode had a higher serum creatinine level vs

148 rformed at the end of therapy showed that no rejection episodes had occurred.

149 ial fraction (30%) of biopsy-confirmed acute rejection episodes have a component of AHR as judged by

150 Recurrent rejection episodes have been linked to the subsequent de

151 Patients experiencing rejection episodes have greater fluctuations in calprote

152 No rejection episodes have occurred.

153 adjusting for DSA_MFI_max, C4d, or previous rejection episodes, however lost their independent relat

154 were found to be at increased risk for acute rejection episodes if the allograft was mismatched for t

155 Allograft impairment was caused by a rejection episode in 84% (32/38) of patients with anti-H

156 d the onset of the first biopsy-proven acute rejection episode in patients with DGF from 29+/-43 days

157 Only 1 patient (0.7%) had a documented rejection episode in the DMEK group compared with 54 (9%

158 P = 0.03) more likely to undergo a > or =3A rejection episode in the first 12 months.

159 between a transplant in the second eye and a rejection episode in the first eye (KC P = .19, FED P =

160 Cumulative incidence of an acute rejection episode in the first year after transplantatio

161 overall relative risk of having at least one rejection episode in those who received fish oil was 0.9

162 There were 23 rejection episodes in 13 patients with seven graft losse

163 The clinical rejection episodes in allografts were significantly asso

164 ection episodes (4/4), whereas there were no rejection episodes in ASK transplants without ATN (0/32;

165 phase II assessment of prophylaxis of acute rejection episodes in deceased donor renal allografts.

166 There were few new acute rejection episodes in either study between years 1 and 2

167 Among the seven rejection episodes in group 1, six of seven occurred amo

168 roids has proven to be effective in reducing rejection episodes in high-risk organ and islet cell tra

169 TN) on graft survival and incidence of acute rejection episodes in infant and small child recipients

170 and long-term rates of repeat and late acute rejection episodes in pediatric heart transplant (PHTx)

171 sporine (CsA) reduces the incidence of acute rejection episodes in renal allograft recipients.

172 ttractive choice for the prevention of acute rejection episodes in renal transplant patients.

173 eported and presumed isolated pancreas acute rejection episodes in simultaneous pancreas kidney patie

174 effective in reducing the incidence of acute rejection episodes in SPKT recipients.

175 All rejection episodes in the non-HLAabs group appeared arou

176 eatinine less than 300 mumol/L with no acute rejection episodes in the preceding 6 months were enroll

177 There were no rejection episodes in this group, and none of them requi

178 The number and severity of rejection episodes increased when the liver was not incl

179 The incidence of graft-rejection episodes is lower after DSEK compared with sta

180 e analysis demonstrated more moderate-severe rejection episodes (ISHLT > or = IIIA) at 2 months (0.83

181 tive probabilities of infection, first acute rejection episode, malignancy, de novo donor specific an

182 intestinal allograft, delay in treatment of rejection episodes may result in rejection of the intest

183 fter randomization 23 patients experienced a rejection episode: MMF/pred (27.0%), MMF/CsA (6.8%) and

184 The patient has had neither rejection episodes nor clinical manifestations of graft-

185 d IL-10 genes were not associated with acute rejection episodes, nor was the IL-4 receptor alpha-chai

186 Although rejection episodes occasionally required restoration of

187 nsplant recipients and, in many cases, acute rejection episodes occur because of escape of donor-reac

188 Most of the rejection episode occurred approximately 1 or 6 months a

189 emonstrated late endothelial failure, and no rejection episodes occurred (0%).

190 Rejection episodes occurred between 0.8 and 34 months.

191 ; Tac/MMF, 2.2%; triple therapy, 2.2%); Most rejection episodes occurred during the first 6 months of

192 Rejection episodes occurred in 9 of 17 IVIG and 1 of 10

193 Three acute rejection episodes occurred in the intervention group.

194 Biopsy-proven acute rejection episodes occurred in three patients (two in th

195 Rejection episodes occurred throughout the first year bu

196 No hyperacute rejection episodes occurred.

197 eterioration of graft function resulted from rejection episodes occurring more than 2 years after tra

198 A tolerant patient had a moderate rejection episode of 5.3 years after immunosuppression w

199 ents with a positive virtual XMs showed more rejection episodes of any types when comparing with pati

200 ollow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ f

201 For example, multiple rejection episodes of the skin have been noted in clinic

202 cal course was complicated by an early acute rejection episode on posttransplant day (PTD) 6, that wa

203 The effect of an acute rejection episode on the risk of developing CAF seems to

204 the incidence of acute rejection, number of rejection episodes or 1-year allograft survival among Bw

205 to the regimen when patients developed acute rejection episodes or adverse effects to steroids or MMF

206 it did not further reduce the rate of acute rejection episodes or increase graft survival compared t

207 no significant difference in cold ischemia, rejection episodes, or patient or graft survival.

208 in initial function, endoscopic appearance, rejection episodes, or transplant pancreatitis.

209 etween particular cytokine profile and early rejection episodes, our data strongly suggest an associa

210 who were TRI negative to have had a previous rejection episode (P=0.02).

211 er incidence of subsequent antibody-mediated rejection episodes (P < 0.001), but reduced death-censor

212 experienced earlier and more frequent acute rejection episodes (P=0.025).

213 The G group had a trend toward earlier rejection episodes (P=0.07), a significantly higher seru

214 Neither acute rejection episodes (P=0.34) nor OKT3 use (P=0.36) before

215 er rate and higher histologic grade of acute rejection episodes, particularly proximate to the onset

216 onrandomized cohorts were compared for acute rejection episodes, patient and graft survival rates, re

217 In addition, the number of rejection episodes per patient as well as renal function

218 Average number of rejection episodes per patient totalled 1.6+/-1.2.

219 approaches, based on; i) DSA levels and ii) rejection episode post transplant.

220 presumed reason for graft failure had prior rejection episodes, potentially suggesting that alloimmu

221 the graft tubular epithelium during clinical rejection episodes, predicting a causal role for CD103+C

222 Any rejection episode prior to PK failure was a significant

223 comitant with the bout of HUS, namely, acute rejection episodes prior to (n=2) or during (n=3), and 2

224 Acute renal allograft rejection episodes refractory to antilymphocyte preparat

225 th the age or sex of the donor or recipient, rejection episodes, renal biopsy, or drug-induced nephro

226 emergency hospitalizations, renal biopsies, rejection episodes, renal function, and blood concentrat

227 The initial rejection episode responded to steroid treatment in 93.4

228 All rejection episodes responded to treatment with alemtuzum

229 four histologically diagnosed, severe acute rejection episodes resulted in graft failure before reso

230 tion, survival of patients and grafts, acute rejection episodes, serum creatinine values, adverse eve

231 Samples taken at the time of a corneal rejection episode showed Fas mRNA levels were significan

232 from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL

233 T cell-mediated rejection episodes tended to be relatively mild-50% (5 e

234 had a 15 times lesser risk of experiencing a rejection episode than DSEK eyes (95% confidence limit [

235 -G levels were higher in patients with acute rejection episodes than nonrejectors.

236 unction displayed a lower incidence of acute rejection episodes than those with later recovery of fun

237 The sixth allograft had an early, severe rejection episode that limited renal growth and attainme

238 lotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by i

239 Despite the rejection episodes, the vast majority of recipients had

240 Despite the high incidence of acute rejection episodes, they can be completely reversed when

241 cumulative probability of immunologic graft rejection episodes through 2 years after DMEK.

242 Numbers of acute rejection episodes, transplantation for autoimmune disea

243 ere collected on patient and graft survival, rejection episodes, urinary tract infection (UTI) requir

244 re higher in patients who subsequently had a rejection episode versus those who had no rejection (22.

245 decrease in TTV-DNA levels for a subsequent rejection episode was 0.74 with a specificity of 0.99.

246 The 3-year predicted probability of a rejection episode was 9% with DSAEK versus 20% with PKP

247 The rate of at least one rejection episode was also significantly higher in the S

248 A rejection episode was considered to have occurred based

249 However, the incidence of a first reversible rejection episode was significantly higher for simultane

250 The incidence of rejection episodes was 15% in both groups.

251 , the incidence of moderate and severe acute rejection episodes was found to be significantly lower a

252 The number of rejection episodes was highest in group 4 and lowest in

253 ariate analysis, the cumulative incidence of rejection episodes was influenced by recipient age (P =

254 A higher incidence of rejection episodes was observed in young patients (<20 y

255 The cumulative incidence of rejection episodes was significantly greater in the no s

256 The incidence of rejection episodes was significantly higher in pretransp

257 The incidence of acute rejection episodes was significantly lower among group 1

258 The incidence and severity of acute rejection episodes was similar between both groups (7.8%

259 roscopy images before, during, and after the rejection episode were analyzed and compared with a case

260 Patients with a graft rejection episode were followed up for 1 additional year

261 No serious or severe adverse events and no rejection episode were reported.

262 ients (1995-2005), 108 patients with a first rejection episode were selected for study using strict i

263 rior glaucoma surgeries, and occurrence of a rejection episode were the significant risk factors for

264 At 6 months, the rates of acute rejection episodes were 38.1% in the ISIS 2302 group ver

265 Graft survival and rejection episodes were analyzed in this group and compa

266 led that grades indicating more severe acute rejection episodes were associated with a greater probab

267 Nine of 13 rejection episodes were associated with noncompliance.

268 Four of the 14 moderate acute rejection episodes were associated with unfavorable clin

269 The majority of rejection episodes were Banff grade I and IIA and were f

270 All rejection episodes were biopsy confirmed.

271 ring the first posttransplant year the acute rejection episodes were characterized by reversible oede

272 imited to azathioprine and prednisone, acute rejection episodes were common, and it was difficult to

273 Among the 3268 biopsies, 180 acute rejection episodes were diagnosed (88 indeterminate, 74

274 All acute rejection episodes were documented by biopsy and were cl

275 No rejection episodes were documented during the PVAN treat

276 Rejection episodes were evaluated after exclusion of pat

277 ent survivals, reason for graft failure, and rejection episodes were evaluated in 221 intestinal reci

278 A total of 299 cases of rejection episodes were identified, of which 145 (48.5%)

279 In nontolerant recipients rejection episodes were mild and resolved over 5.6 month

280 Rejection episodes were more likely to be irreversible f

281 rast, the 74 mild and 88 indeterminate acute rejection episodes were not associated with unfavorable

282 Rejection episodes were not observed in the three macroc

283 However, rejection episodes were not significantly different amon

284 onor-specific human leukocyte antigen Abs or rejection episodes were noted, even though the patients

285 rrelated well with HA titers and importantly rejection episodes were preempted by a rising relative m

286 Rejection episodes were restricted to the pediatric CAD

287 Graft rejection episodes were seen in 5 eyes (12.1%) in the PK

288 Rejection episodes were seen in a greater proportion of

289 ollected according to center protocol and at rejection episodes, were retrospectively included (n = 2

290 nd year after DMEK, whereas 6% experienced a rejection episode when steroids were discontinued.

291 One patient experienced a clinical rejection episode, which was successfully treated.

292 nts experiencing a first biopsy-proven acute rejection episode while receiving CsA-ME were randomized

293 he lowest MR2* levels were observed in acute rejection episodes with vascular injury i.e. IIA and C4d

294 es with no rejection and the occurrence of a rejection episode within 2 months.

295 significantly reduced risk of experiencing a rejection episode within 2 years after surgery compared

296 highly predictive of clinically significant rejection episodes within 1 year of orthotopic heart tra

297 ad multiple biopsy proven or severe clinical rejection episodes within the first 21 days and only one

298 %, or 25.7% incidence of biopsy-proven acute rejection episodes within the first 6 months posttranspl

299 All patients developed reversible rejection episodes within the first month that were char

300 eripheral blood leukocyte genes that trigger rejection episodes would be evident late after ITx durin